Intec Pharma (NTEC) and Its Peers Head-To-Head Contrast

Intec Pharma (NASDAQ: NTEC) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Intec Pharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Intec Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intec Pharma N/A N/A N/A
Intec Pharma Competitors -5,248.95% -210.61% -37.96%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intec Pharma and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intec Pharma 0 0 4 0 3.00
Intec Pharma Competitors 887 3274 11772 235 2.70

Intec Pharma presently has a consensus target price of $12.00, indicating a potential upside of 133.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.56%. Given Intec Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Intec Pharma is more favorable than its rivals.

Earnings and Valuation

This table compares Intec Pharma and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intec Pharma N/A -$13.36 million -4.40
Intec Pharma Competitors $284.49 million $34.10 million 62.56

Intec Pharma’s rivals have higher revenue and earnings than Intec Pharma. Intec Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

40.2% of Intec Pharma shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

What are top analysts saying about Intec Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intec Pharma and related companies.

Intec Pharma (NTEC) and Its Peers Head-To-Head Contrast

Intec Pharma (NASDAQ: NTEC) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Intec Pharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Intec Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intec Pharma N/A N/A N/A
Intec Pharma Competitors -5,248.95% -210.61% -37.96%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intec Pharma and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intec Pharma 0 0 4 0 3.00
Intec Pharma Competitors 887 3274 11772 235 2.70

Intec Pharma presently has a consensus target price of $12.00, indicating a potential upside of 133.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.56%. Given Intec Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Intec Pharma is more favorable than its rivals.

Earnings and Valuation

This table compares Intec Pharma and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intec Pharma N/A -$13.36 million -4.40
Intec Pharma Competitors $284.49 million $34.10 million 62.56

Intec Pharma’s rivals have higher revenue and earnings than Intec Pharma. Intec Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

40.2% of Intec Pharma shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

What are top analysts saying about Intec Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intec Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit